Slide 1: Welcome to the 1Q26 webinar
Welcome to the 1Q26 webinar April 24, 2026
Slide 2: Today's agenda
Today’s agenda ▪ This is Modulight ▪ Q1 in nutshell ▪ Financial highlights ▪ R&D pipeline progress ▪ Strategy update ▪ Outlook ▪ Summary ▪ Q&A
Slide 3: Modulight
modulight
Slide 4: We fight cancer with science and technology
We fight cancer with science and technology ▪ We are a life science company that designs and manufactures laser devices for the treatment of cancer and eye diseases ▪ We also manufacture products for other high- value applications such as flow cytometry, microscopy, semiconductor, quantum, and defen
Slide 5: Q1 in brief
Q1 in brief ▪ EBITDA improved 157% from 1Q25, reaching 22% Q1 ▪ Pipeline is progressing (36 projects) and customer base & product mix EBITDA increased by continues to diversify 157% compared to the ▪ Customer activity & positive feedback same period last year. about product platform particular PPT s
Slide 6: Financial highlights Jan-Mar 2026
Financial highlights Jan-Mar 2026 ▪ PPT business continues good progressing in terms of number of indications and sites ▪ Revenue was 7% lower than in the Revenue EBITDA EBIT corresponding period of 2025 ▪ EBITDA was at 22% which is an improvement of 157% due to continuous focus on operational EUR E
Slide 7: Key figures
Key figures Group EUR 1,000 unless otherwise noted 1–3/2026 1–3/2025 1–12/2025 1) Revenue 1,495 1,606 7,069 EBITDA 330 -582 -168 EBITDA - % 22.1% -36.2% -2.4 % Operating result (EBIT) -1,064 -1,585 -4,648 Operating result (EBIT) - % -71.2% -98.7% -65.8 % Earnings for the period -958 -1,616 -4,604 Ea
Slide 8: Growth in the R&D pipeline
Growth in the R&D pipeline ▪ R&D pipeline grew to 36 (31) projects and growth coming from very large Number of projects with commercialization potential companies – aim in all projects is to commercialize our own products 40 ▪ PPT economics improving and customer commitment increasing 35 ▪ PPT sites
Slide 9: Modulight's customer base
Modulight’s customer base Customer ownership Very large companies share 40 in customer portfolio 35 increases 30 ▪ 44% have over 1bn revenue 25 ▪ 64% of customers are listed companies 20 ▪ 60% are established 15 companies ▪ 31% are privately owned 10 ▪ 6% are research companies 5 0 1Q23 2Q23 3Q23 4Q
Slide 10: Strategy and Targets 2026 – 2027
Strategy and Targets 2026 – 2027 Expansion to new STRATEGIC KEY Development of Scale up Pay Per Operations ramp-up State-of-the-art laser applications & FACTORS existing pipeline Treatment (PPT) using own factory technology indications Life science products & same lasers for other high value-add PRO
Slide 11: Outlook
Outlook The company expects to grow its revenues and EBITDA in the financial year 2026. The purpose of introducing guidance is to increase transparency and improve the predictability of the company’s financial development for investors and other stakeholders. The guidance reflects management’s curre
Slide 12: Summary
Summary ▪ EBITDA improved 157% from 1Q25, reaching 22% Q1 & Sales -7% YoY ▪ Pipeline is increasing and share of large customers is now 44% (35%) ▪ Customer activity & positive feedback about product platform particular PPT sites & semiconductors ▪ Cost savings & increase in productivity ▪ Revenue wa
Slide 13: Thank you!
Thank you! Questions?
Slide 14: Updated strategy with focused actions 2026 – 2027
Updated strategy with focused actions 2026 – 2027 Strategy (2023 – 2025) Strategy and targets 2023 - 2025 is sound but requires more time ▪ Increased and diversified pipeline in accordance with the strategy 1 ▪ PPT launched as new business model 2 ▪ Several customers now in 3 phase3 /pilot productio